Clinical Context
A patient with a rare or newly approved biologic therapy is scheduled to receive an outpatient infusion or injection billed under the unclassified HCPCS Level II code C9399 when no specific J‑code exists. Typical patients include those with refractory autoimmune diseases, rare hematologic disorders, or oncology indications for which the product is not yet assigned a permanent HCPCS code. The clinical workflow begins with a prescribing clinician (for example, a rheumatologist, hematologist/oncologist, or immunologist) documenting medical necessity and indication in the chart. The drug is obtained by the infusion center or pharmacy and verified by pharmacy staff for dosing and lot information. On the day of service the patient undergoes standard pre‑infusion assessment (vital signs, allergy check), informed consent when required, and administration by an infusion nurse or clinician. Medication preparation, administration time, and any monitoring or complication management (e.g., treatment of infusion reactions, additional observation time) are documented. Billing staff append C9399 with an appropriate modifier (for example, JW for discarded drug, JG is not listed so not used) and include drug name, strength, NDC, quantity, and route on the claim and in supporting documentation. Payer adjudication may require submitted manufacturer invoice, itemized drug receipt, and clinical notes demonstrating medical necessity. Typical sites of service are outpatient hospital infusion centers, physician office infusion suites, and specialty ambulatory infusion clinics. Patient scenario example: a 58‑year‑old with refractory autoimmune hemolytic anemia receives a novel biologic available through limited distribution; the hospital pharmacy prepares the dose, the patient is monitored for two hours post‑infusion for infusion‑related reactions, and the service is billed using C9399 with modifier JW for the portion discarded and modifier 52 if a reduced dose is administered due to tolerance concerns.